Veneta 10 mg (Tablet)
Unit Price: ৳ 50.00 (3 x 10: ৳ 1,500.00)
Strip Price: ৳ 500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Venetoclax |
| Company | Drug international ltd |
| Also available as |
Indications
- Treatment of chronic lymphocytic leukemia (CLL) in adult patients
- Monotherapy for CLL in adult patients with specific genetic mutations
- Indicated for CLL patients unsuitable for or failed B-cell receptor pathway inhibitor
- Indicated when patients have failed both chemoimmunotherapy and B-cell receptor pathway inhibitor
Pharmacology
- Selective and orally bioavailable small-molecule inhibitor of BCL-2
- Restores process of apoptosis by displacing pro-apoptotic proteins
- Triggers mitochondrial outer membrane permeabilization
- Demonstrated cytotoxic activity in tumor cells overexpressing BCL-2
Dosage & Administration
- Starting dose: 20 mg once daily for 7 days
- Gradual increase to daily dose of 400 mg over 5 weeks
- Recommended post-titration dose for combination therapy
- Recommended post-titration dose for monotherapy
Interaction
- Contraindicated with strong CYP3A inhibitors at initiation and during titration phase
- Use with moderate CYP3A inhibitors requires dose reduction
- Avoid concomitant use with P-gp and BCRP inhibitors during dose-titration phase
- Dose reductions required when used with CYP3A inducers
Contraindications
- Hypersensitivity to active substance or excipients
- Concurrent use of strong CYP3A inhibitors
- Concurrent use of preparations containing St. John's wort
Side Effects
- Common side effects include neutropenia, diarrhea, and upper respiratory tract infection
- Serious side effects may include pneumonia, febrile neutropenia, and tumor lysis syndrome (TLS)
Pregnancy & Lactation
- Women of childbearing potential must use highly effective contraception
- Avoid becoming pregnant while taking Venetoclax and for at least 30 days after treatment
- Not recommended during pregnancy and in women not using contraception
- Breast-feeding should be discontinued during treatment
Precautions & Warnings
- High risk of tumor lysis syndrome (TLS) in initial dose-titration phase
- Monitoring and management of electrolyte abnormalities required
- Dose reductions or interruptions recommended for severe neutropenia
- Immunization with live attenuated vaccines not studied
- Highly effective contraception required for women of childbearing potential
Use in Special Populations
- No specific dose adjustment for elderly patients
- No dose adjustment for patients with mild or moderate renal impairment
- Safety in severe renal impairment or on dialysis not established
- No specific dose adjustment for patients with mild or moderate hepatic impairment
Overdose Effects
- No specific antidote available
- Close monitoring and supportive treatment recommended
- Treatment interruption and careful monitoring for TLS symptoms during overdose
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store below 30°C
- Protect from moisture and light
- Keep out of the sight and reach of children